dc.contributor.author | Kiselev, Yury | |
dc.date.accessioned | 2020-12-09T08:30:19Z | |
dc.date.accessioned | 2021-02-17T09:52:33Z | |
dc.date.available | 2020-12-09T08:30:19Z | |
dc.date.available | 2021-02-17T09:52:33Z | |
dc.date.issued | 2020-12-08 | |
dc.identifier.citation | Kiselev Y. Nationwide Study of Neuropsychiatric Comorbidity and Medicines Use in Children With Autism Spectrum Disorder in Norway. Frontiers in Psychiatry. 2020 | en |
dc.identifier.issn | 1664-0640 | |
dc.identifier.uri | https://hdl.handle.net/10642/9587 | |
dc.description.abstract | Purpose: Autism spectrum disorder (ASD) has a high rate of comorbidity. While many
children with ASD are exposed to psychotropic medicines, their efficacy and safety
in these patients are unclear. There is a need for more detailed knowledge on which
medicines are most commonly used and for which disorders. We aimed to investigate
(a) prevalence and incidence rate of ASD among Norwegian children, and further, among
newly diagnosed ASD children in 2014, study the (b) co-occurrence of neuropsychiatric
disorders, (c) use of psychotropic drugs, and (d) the relationship between co-occurring
diagnoses and use of psychotropic drugs.
Method: Nationwide registry-based study of children 2–17 years old in Norway.
Results: The ASD prevalence was 0.76% and the incidence rate was 0.12% in 2014.
Of the children who received an initial ASD diagnosis in 2014 (n = 1,234), 64.8% had
one or more co-occurring neuropsychiatric diagnosis. Psychotropic medication use was
moderate (∼20% used stimulants or hypnotics) in general, and low in children without
comorbidity (nearly only hypnotics). There was a good accordance between co-occurring
diagnoses and indication for the prescribed medications.
Conclusions: Children with newly diagnosed ASD mainly received psychotropic drugs
to treat co-occurring neuropsychiatric conditions. | en |
dc.description.sponsorship | This study was funded by the Norwegian Institute of Public Health (NIPH) and Oslo Metropolitan University (OsloMet). | en |
dc.language.iso | en | en |
dc.publisher | Frontiers Media | en |
dc.relation.ispartofseries | Frontiers in Psychiatry;December 2020 | Volume 11 | Article 596032 | |
dc.rights | Creative Commons Attribution 4.0 International (CC BY 4.0) License | en |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Autism | en |
dc.subject | Children | en |
dc.subject | Psychotropic medicines | en |
dc.subject | Co-occurring neuropsychiatric diagnoses | en |
dc.subject | Medication use | en |
dc.title | Nationwide Study of Neuropsychiatric Comorbidity and Medicines Use in Children With Autism Spectrum Disorder in Norway | en |
dc.type | Journal article | en |
dc.type | Peer reviewed | en |
dc.date.updated | 2020-12-09T08:30:19Z | |
dc.description.version | publishedVersion | en |
dc.identifier.doi | https://doi.org/10.3389/fpsyt.2020.596032 | |
dc.identifier.cristin | 1857764 | |
dc.source.journal | Frontiers in Psychiatry | |